TABLE 2.
Efficacies of eravacycline and comparators in a mouse septicemia model with intraperitoneal challenge
| Organism | PD50, mg/kg i.v. (95% CI) |
|||||
|---|---|---|---|---|---|---|
| Eravacycline | Tigecycline | Tetracycline | Vancomycin | Linezolid | Imipenem | |
| S. aureus ATCC 13709 | 0.30 (0.29 to 0.31) | 0.32 ± 0.07a | NTb | NT | NT | NT |
| MRSA SA161 [tet(M)] | 1.0 (0.56 to 1.4) | 1.0 (0.78 to 1.2) | >10 | NT | NT | NT |
| MRSA SA192 [tet(K) USA300] | 0.30 (0.13 to 0.47) | 0.35 (0.34 to 0.37) | >10 | 0.30 (0.15 to 0.45) | NT | NT |
| S. pyogenes ATCC 8668 | 1.0 (0.78 to 1.2) | 2.5 (1.7 to 3.4) | NT | NT | >10 | NT |
| S. pyogenes ATCC 19615 | ∼0.05 (—c) | 0.30 (0.04 to 0.56) | NT | NT | 0.63 (0.06 to 1.2) | NT |
| E. coli ATCC 25922 | 4.4 (−0.01 to 8.7) | 1.7 (0.91 to 2.6) | NT | NT | NT | NT |
| E. coli EC133 [ESBL+ (blaSHV) tet(B) tet(D)] | 1.2 (0.84 to 1.6) | 3.5 (2.4 to 4.7) | NT | NT | NT | <0.3 |
a
Mean and standard deviation (SD) from three experiments.
b
NT, not tested.
c
—, PD50 is estimated and a 95% CI could not be determined due to the significant activity of eravacycline against this strain.